A. . Friedlaender, “Impact of performance status on non-small-cell lung cancer patients with a PD-L1 tumour proportion score ≥50% treated with front-line pembrolizumab”, AO, vol. 59, no. 9, pp. 1058–1063, Sep. 2020.